Internal compliance reviews are not enough; life sciences companies need to assess their third-party business partners
Yogesh Bahl, AlixPartners, LLP
Advertisement
Articles by Yogesh Bahl, AlixPartners, LLP
Advertisement
Latest Updated Articles
- Managing third-party risks in the life sciences industry
Published: January 27th 2015 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Novo Nordisk’s Bloomington Plant Receives FDA OAI Designation Following Contamination and Compliance Issues
2
Why Regulatory Sandboxes Offer a Safe Space for AI Innovation in Healthcare
3
Pharma Pulse: CDC Layoffs Raise Public Health Concerns as Ypsomed and Lupin Expand US Manufacturing Footprint
4
LogiPharma USA 2025: What Topics Do You Think Will headline the 25th LogiPharma USA?
5
